Literature DB >> 27323707

Foot-and-mouth disease virus genome replication is unaffected by inhibition of type III phosphatidylinositol-4-kinases.

Eleni-Anna Loundras1, Morgan R Herod1, Mark Harris1, Nicola J Stonehouse1.   

Abstract

Foot-and-mouth disease virus (FMDV) causes economically damaging infections of cloven-hooved animals, with outbreaks resulting in large financial losses to the agricultural industry. Due to the highly contagious nature of FMDV, research with infectious virus is restricted to a limited number of key facilities worldwide. FMDV sub-genomic replicons are therefore important tools for the study of viral translation and genome replication. The type III phosphatidylinositol-4-kinases (PI4Ks) are a family of enzymes that plays a key role in the production of replication complexes (viral factories) of a number of positive-sense RNA viruses and represents a potential target for novel pan-viral therapeutics. Here, we investigated whether type III PI4Ks also play a role in the FMDV life cycle, using a combination of FMDV sub-genomic replicons and bicistronic internal ribosome entry site (IRES)-containing reporter plasmids. We demonstrated that replication of the FMDV replicon was unaffected by inhibitors of either PI4KIIIα or PI4KIIIβ. However, PIK93, an inhibitor previously demonstrated to target PI4KIIIβ, did inhibit IRES-mediated protein translation. Consistent with this, cells transfected with FMDV replicons did not exhibit elevated levels of phosphatidylinositol-4-phosphate lipids. These results are therefore supportive of the hypothesis that FMDV genome replication does not require type III PI4K activity and does not activate these kinases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27323707      PMCID: PMC5042127          DOI: 10.1099/jgv.0.000527

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  46 in total

Review 1.  Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001.

Authors:  D Thompson; P Muriel; D Russell; P Osborne; A Bromley; M Rowland; S Creigh-Tyte; C Brown
Journal:  Rev Sci Tech       Date:  2002-12       Impact factor: 1.181

2.  Hijacking components of the cellular secretory pathway for replication of poliovirus RNA.

Authors:  George A Belov; Nihal Altan-Bonnet; Gennadiy Kovtunovych; Catherine L Jackson; Jennifer Lippincott-Schwartz; Ellie Ehrenfeld
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.

Authors:  Michael J Waring; David M Andrews; Paul F Faulder; Vikki Flemington; Jennifer C McKelvie; Sarita Maman; Marian Preston; Piotr Raubo; Graeme R Robb; Karen Roberts; Rachel Rowlinson; James M Smith; Martin E Swarbrick; Iris Treinies; Jon J G Winter; Robert J Wood
Journal:  Chem Commun (Camb)       Date:  2013-12-24       Impact factor: 6.222

4.  Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα).

Authors:  Piotr Raubo; David M Andrews; Jennifer C McKelvie; Graeme R Robb; James M Smith; Martin E Swarbrick; Michael J Waring
Journal:  Bioorg Med Chem Lett       Date:  2015-06-04       Impact factor: 2.823

5.  Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4 gamma.

Authors:  R Kirchweger; E Ziegler; B J Lamphear; D Waters; H D Liebig; W Sommergruber; F Sobrino; C Hohenadl; D Blaas; R E Rhoads
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Replication-competent foot-and-mouth disease virus RNAs lacking capsid coding sequences.

Authors:  G M McInerney; A M King; N Ross-Smith; G J Belsham
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

7.  The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.

Authors:  David L Wyles; Kelly A Kaihara; Brent E Korba; Robert T Schooley; James R Beadle; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

8.  Internal ribosome entry site within hepatitis C virus RNA.

Authors:  K Tsukiyama-Kohara; N Iizuka; M Kohara; A Nomoto
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

10.  Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.

Authors:  Minetaro Arita; Hirotatsu Kojima; Tetsuo Nagano; Takayoshi Okabe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2010-12-22       Impact factor: 6.549

View more
  3 in total

1.  Foot-and-Mouth Disease Virus 3A Hijacks Sar1 and Sec12 for ER Remodeling in a COPII-Independent Manner.

Authors:  Heng-Wei Lee; Yi-Fan Jiang; Hui-Wen Chang; Ivan-Chen Cheng
Journal:  Viruses       Date:  2022-04-18       Impact factor: 5.818

2.  Investigation of the Role of Protein Kinase D in Human Rhinovirus Replication.

Authors:  Anabel Guedán; Dawid Swieboda; Mark Charles; Marie Toussaint; Sebastian L Johnston; Amin Asfor; Anusha Panjwani; Tobias J Tuthill; Henry Danahay; Tony Raynham; Aurelie Mousnier; Roberto Solari
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 3.  Current Practice in Bicistronic IRES Reporter Use: A Systematic Review.

Authors:  Guus Gijsbertus Hubert van den Akker; Federico Zacchini; Bas Adrianus Catharina Housmans; Laura van der Vloet; Marjolein Maria Johanna Caron; Lorenzo Montanaro; Tim Johannes Maria Welting
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.